Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507865-24-00

Acronym

CJPB898A12301

Enrollment

302

Registered

2024-07-17

Start date

2025-03-28

Completion date

2025-10-27

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced (unresectable/metastatic) melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Czechia, Germany, Greece, Hungary, Italy, Lithuania, Poland, Portugal, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026